Benitec Biopharma Inc

For the period ended Jun 30, 2024. Filed Sep 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 26, 2024

BNTC$9.28-6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Loss · Total Stockholders’ Equity
Shares · Amount
Balance at June 30, 2022	506,222	$—	$152,454	$(148,327)	$(1,245)	$2,882
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869	1,037,520	—	16,015	—	—	16,015
Exercise of pre-funded warrants	127,743	—	—	—	—	—
Share-based compensation	—	—	452	—	—	452
Foreign currency translation gain	—	—	—	—	415	415
Net loss	—	—	—	(19,562)	—	(19,562)
Balance at June 30, 2023	1,671,485	$—	$168,921	$(167,889)	$(830)	$202
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964	875,949	—	27,919			27,919
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $2,928	5,749,152	1	37,071	—	—	37,072
Exercise of pre-funded warrants	953,307	—	—	—	—	—
Exercise of Series 2 warrants	98,039	—	190	—	—	190
Exercise of common warrants	738,187	—	2,848	—	—	2,848
Anti-dilution adjustment to warrants	—	—	619	(619)	—	—
Share-based compensation	—	—	830	—	—	830
Foreign currency translation gain	—	—	—	—	(62)	(62)
Net loss	—	—	—	(21,751)	—	(21,751)
Balance at June 30, 2024	10,086,119	$1	$238,398	$(190,259)	$(892)	$47,248

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.